Drug intelligence / Profile preview

LYT-200 + gemcitabine + nab-paclitaxel

Development stage: Unknown
Lead developer: Gallop Oncology
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LYT-200 + gemcitabine + nab-paclitaxel is an investigational combination regimen being tested in clinical trials for advanced/metastatic solid tumors, including head and neck squamous cell carcinoma. LYT-200 is a fully human IgG4 monoclonal antibody developed to inhibit galectin-9, an immunosuppressive and pro-tumor molecule expressed in various cancers. Gemcitabine is a nucleoside analog chemotherapeutic (antimetabolite), and nab-paclitaxel is a nanoparticle albumin-bound formulation of the antimitotic agent paclitaxel. This combination aims to harness the direct anti-tumor effects of chemotherapy and the immune-modulating activity of LYT-200, which downregulates galectin-9, activates NK and T cells, and enhances immune-mediated tumor clearance.

Brand names: Abraxane (nab-paclitaxel)
Other names: nab-paclitaxelGemzar (gemcitabine)

Targets

TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)LGALS9 (Galectin-9)CDA (Cytidine deaminase)DNA polymerase family

Beyond the preview

Go deeper on LYT-200 + gemcitabine + nab-paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYT-200 + gemcitabine + nab-paclitaxel.

Explore the full profile